Evidence map›Paper›PMID 33900435›Full record

ArticleJournal of cancer research and clinical oncology2021

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Alessandro Leonetti, Daniela Carbone, Alessandro Gregori, Marcello Tiseo, Godefridus J Peters, Dongmei Deng, Elisa Giovannetti

Open access · greenAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Alessandro Leonetti *Department of Medicine and Surgery, University of Parma, Parma, Italy.
Daniela Carbone *Department of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Alessandro GregoriDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Marcello TiseoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Godefridus J PetersDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Dongmei DengDepartment of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
Elisa GiovannettiDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. e.giovannetti@amsterdamumc.nl.ORCID 0000-0002-7565-7504
Cancer Center Amsterdam · NLUniversity of Parma · ITAcademic Center for Dentistry Amsterdam · NLFondazione Pisa · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG24444Cancer Center Amsterdam 2016 and 2018KWF Kankerbestrijding 11957Polish National Science Center 2018/31/B/NZ7/02909
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lung NeoplasmsMycoplasmaAcrylamidesAniline CompoundsCytidine DeaminaseErbB ReceptorsHumansIndolesPyrimidinesAcrylamidesAniline CompoundsCytidine DeaminaseEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidines

Identifiers

PMID33900435
PMCPMC11802145
OpenAlexW3159901544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.